Related Experiment Videos
[Long term experiences with a solid spironolactone-furosemide combination in heart insufficiency and hypertension]
Insights
Osyrol 50-Lasix effectively treated edema and heart insufficiency in patients. The medication normalized blood pressure in hypertensive individuals and showed good tolerability with minimal side effects.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Patients with advanced heart failure (stages III-IV) often experience edema and hypertension.
- Effective management of these symptoms is crucial for improving patient outcomes.
Purpose:
- To evaluate the efficacy and tolerability of Osyrol 50-Lasix in patients with cardiac insufficiency and concomitant hypertension.
- To assess the drug's impact on edema, cardiac compensation, blood pressure, and key laboratory parameters.
Summary:
- A three-month study treated 19 patients with Osyrol 50-Lasix, achieving significant edema reduction and cardiac recompensation.
- Hypertensive patients experienced normalized blood pressure, while serum potassium, creatinine, uric acid, and glucose levels remained stable.
- Therapeutic success was rated good in 18 patients, with good tolerability reported in most cases.
Impact:
- Osyrol 50-Lasix demonstrates significant efficacy in managing edema and improving cardiac function in heart failure patients.
- The drug effectively normalizes blood pressure in hypertensive individuals with heart failure.
- Favorable tolerability profile suggests Osyrol 50-Lasix as a viable treatment option for this patient population.
Abstract:
Nineteen ambulant patients in cardiac insufficiency stages III to IV, eleven of them concomitantly presenting hypertension, were treated with Osyrol 50-Lasix for a period of three months. With a maintenance dose consisting on average of one capsule Osyrol 50-Lasix daily, effective and reliable elimination of edema and adequate recompensation of the heart was achieved by way of reduction of the body weight, decrease in ankle circumference, congestion of the liver and improvement of dyspnoea. In the eleven patients with hypertension grade I, the systolic and diastolic blood pressure was normalized under Osyrol 50-Lasix medication, whilst the blood pressure values of normotensive patients were practically unchanged. The serum potassium values at the beginning of the study were 4.29 mmol/l on average and increased moderately to 4.83 mmol/l after three months' therapy. Compared to pre-trial controls the serum values of creatinine and uric acid showed no changes attributable to the drug after three months' therapy with Osryol 50-Lasix. No significant change of the fasting blood glucose values was ascertained either in the nondiabetic or in the diabetic patients. Based on the clinical and laboratory-chemical parameters the success of therapy was considered to be good in 18 patients and satisfactory in one case. Tolerability was also considered to be good in 18 cases. Transient side effects were observed in two patients. Hypotension was diagnosed in one case after four weeks' treatment and in a further patient an increased serum potassium level was found. After reducing the dose the values reverted to normal in both cases.